Sight Sciences Announces the OMNI® Surgical System to be Included in UnitedHealthcare's® Expanded Coverage of Glaucoma Surgical Treatments

Core Insights - UnitedHealthcare (UHC) has updated its policy to cover specific glaucoma surgical treatments, including goniotomy, trabeculotomy, canaloplasty (ab interno), and combined canaloplasty and trabeculotomy for adults aged 19 and older, when medically necessary for treating mild to moderate open-angle glaucoma and cataract [1][2][3] Group 1: Company Overview - Sight Sciences, Inc. is an eyecare technology company focused on developing and commercializing innovative interventional technologies aimed at transforming care and improving patients' lives [1][4] - The company's OMNI Surgical System is FDA-cleared for canaloplasty followed by trabeculotomy to reduce intraocular pressure in adult patients with primary open-angle glaucoma [3][4] - Sight Sciences also offers the TearCare System, which is cleared for localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland disease [4] Group 2: Market Impact - The updated coverage policy by UHC, effective October 1, 2025, will apply to UHC's commercial and individual exchange benefit plans, which cover approximately 30 million of the over 50 million total covered lives under UHC [2] - This expanded coverage for minimally invasive glaucoma surgery (MIGS) procedures, including the OMNI technology, is expected to enhance access for UHC members when deemed medically necessary by their ophthalmologist [3]